<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03892772</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000421</org_study_id>
    <nct_id>NCT03892772</nct_id>
  </id_info>
  <brief_title>Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea</brief_title>
  <acronym>ComboPlus</acronym>
  <official_title>Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apnimed</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, there is no pharmacological intervention for OSA that targets multiple
      pathophysiological deficits in combination. Here the investigators study the effect on sleep
      apnea severity of combinations of pharmacological agents that stimulate the pharyngeal
      muscles, stabilize ventilatory control, and increase the arousal threshold.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of the current study is to determine the effect of combination therapy
      targeting phenotypic traits on OSA severity. Specifically, the investigators will assess the
      effect of combination pharmacological therapy on OSA severity as measured by the
      apnea-hypopnea index and the arousal index (co-primary outcome variables).

      The investigators will also estimate the effects of the interventions on the physiological
      traits responsible for OSA using polysomnography, namely:

        -  Pharyngeal anatomy and its propensity towards collapse

        -  The ability of the upper airway dilator muscles to activate and reopen the airway during
           sleep (i.e. neuromuscular compensation)

        -  Arousal threshold from sleep (i.e. the propensity for hypopneas/apneas to lead to
           arousal and fragmented sleep).

        -  Stability of the ventilatory control system feedback loop (i.e. loop gain). Baseline
           traits will be used to examine whether patient characteristics influence the responses
           to each combination of interventions (i.e. muscles, muscles plus loop gain, muscles plus
           arousal threshold).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apnea-hypopnea index [AHI]</measure>
    <time_frame>3 days</time_frame>
    <description>Apneas and hypopneas per hour (3% desat and/or arousal), % change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoxic Burden</measure>
    <time_frame>3 days</time_frame>
    <description>Desaturation area under curve Ã— event frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Total Sleep Time in non-REM Stage 1</measure>
    <time_frame>3 days</time_frame>
    <description>% Total sleep time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale for Sleep Quality</measure>
    <time_frame>3 days</time_frame>
    <description>Sleep Quality 0-10 scale, 0 worst sleep quality, 10 best sleep quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale for Waking Unrefreshed</measure>
    <time_frame>3 days</time_frame>
    <description>Waking Unrefreshed 0-10 scale, 0 extremely refreshed, 10 extremely unrefreshed</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Visual Analog Scale for Excessive Fatigue</measure>
    <time_frame>3 days</time_frame>
    <description>Excessive Fatigue 0-10 scale, 0 no fatigue, 10 highly fatigued</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual Analog Scale for Low Energy</measure>
    <time_frame>3 days</time_frame>
    <description>Low Energy 0-10 scale, 0 no trouble with energy, 10 extremely low energy</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual Analog Scale for Treatment Satisfaction</measure>
    <time_frame>3 days</time_frame>
    <description>Treatment Satisfaction 0-10 scale, 0 extremely dissatisfied, 10 extremely satisfied</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>SAS0421a, SAS0421b and SAS0421c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take SAS0421a, SAS0421b and SAS0421c for 3 days. Half doses will be given on the first night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAS0421a and SAS0421b</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will take SAS0421a and SAS0421b for 3 days. Half doses will be given on the first night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAS0421c</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will take SAS0421c for 3 days. Half doses will be given on the first night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will take placebos for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAS0421a</intervention_name>
    <description>treatment will be given for 3 days</description>
    <arm_group_label>SAS0421a and SAS0421b</arm_group_label>
    <arm_group_label>SAS0421a, SAS0421b and SAS0421c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAS0421b</intervention_name>
    <description>treatment will be given for 3 days</description>
    <arm_group_label>SAS0421a and SAS0421b</arm_group_label>
    <arm_group_label>SAS0421a, SAS0421b and SAS0421c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAS0421c</intervention_name>
    <description>treatment will be given for 3 days</description>
    <arm_group_label>SAS0421a, SAS0421b and SAS0421c</arm_group_label>
    <arm_group_label>SAS0421c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo will be given for 3 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Ages 18 - 79 years

          -  Suspected or diagnosed OSA

        Exclusion criteria:

          -  Any uncontrolled medical condition

          -  Current use of the medications under investigation

          -  Use of medications expected to stimulate or depress respiration (including opioids,
             barbiturates, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).

          -  Current use of hypnotic medications (trazodone, eszopiclone, benzodiazepines).

          -  Current use of SNRIs/SSRIs or anticholinergic medications.

          -  Conditions likely to affect obstructive sleep apnea physiology: neuromuscular disease
             or other major neurological disorder, heart failure (also below), or any other
             unstable major medical condition.

          -  Respiratory disorders other than sleep disordered breathing:

        chronic hypoventilation/hypoxemia (awake SaO2 &lt; 92% by oximetry) due to chronic obstructive
        pulmonary disease or other respiratory conditions.

          -  Other sleep disorders: periodic limb movements (periodic limb movement arousal index &gt;
             10/hr), narcolepsy, or parasomnias.

          -  Contraindications for SAS0421a and SAS0421b, including:

               -  hypersensitivity to SAS0421a and SAS0421b (angioedema or urticaria)

               -  pheochromocytoma

               -  use of monoamine oxidase inhibitors

               -  benign prostatic hypertrophy, urinary retention

               -  untreated narrow angle glaucoma

               -  bipolar disorder, mania, psychosis

               -  history of major depressive disorder (age&lt;24).

               -  history of attempted suicide or suicidal ideation within one year prior to
                  screening

               -  clinically significant constipation, gastric retention

               -  pre-existing seizure disorders

               -  clinically-significant kidney disorders (eGFR&lt;60 ml/min/1.73m2)

               -  clinically-significant liver disorders

               -  clinically-significant cardiovascular conditions

               -  severe hypertension (SBP&gt;180 mmHg or DBP&gt;110 mmHg measured at baseline)

               -  cardiomyopathy (LVEF&lt;50%) or heart failure

               -  advanced atherosclerosis

               -  history of cerebrovascular events

               -  history of cardiac arrhythmias e.g., atrial fibrillation, QT prolongation

               -  other serious cardiac conditions that would raise the consequences of an increase
                  in blood pressure or heart rate

               -  myasthenia gravis

               -  pregnancy/breast-feeding

          -  Additional contraindications for SAS0421c, including:

               -  Use more than 500 mg/day of Aspirin

               -  Allergies to this drug class

               -  Adrenocortical insufficiency

               -  Low sodium or potassium

               -  hyperchloremic acidosis

          -  Claustrophobia

          -  Pregnancy or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott A Sands, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bradley A Edwards, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Monash University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott A Sands, PhD</last_name>
    <phone>617-278-0911</phone>
    <email>sasands@bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Hess</last_name>
      <phone>617-732-8976</phone>
      <email>lhess1@bwh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash University</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bradley A Edwards, PhD</last_name>
      <phone>+61 3 9905 0187</phone>
      <email>bradley.edwards@monash.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley A Edwards, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2019</study_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Scott Aaron Sands</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Will IPD be available? Yes What data will be shared? All IPD collected during the study, after deidentification.
When will data be available? Immediately after publication. No end date. With whom? Researchers who provide a methodologically sound proposal. For what types of analyses? Any purpose.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Immediately after publication. No end date.</ipd_time_frame>
    <ipd_access_criteria>1-page proposals should be directed to Dr. Scott Sands (sasands@bwh.harvard.edu). To gain access, requestors will be asked to sign a data use agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

